Extended Data Fig. 6: CSF biomarkers of glia and inflammatory response and endothelial and neuronal cell injury in APOE4 and APOE3carriers.
From: APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
a, CSF astrocytic S100B levels in individuals with CDR 0 bearing APOE3 (black, n = 77) or APOE4 (red, n = 41), and with CDR 0.5 bearing APOE3 (n = 39) or APOE4 (n = 32). b, CSF IL6 levels in individuals with CDR 0 bearing APOE3 (n = 71) or APOE4 (n = 47), and with CDR 0.5 bearing APOE3 (n = 34) or APOE4 (n = 32). c, CSF IFNγ levels in individuals with CDR 0 bearing APOE3 (n = 54) or APOE4 (n = 29), and with CDR 0.5 bearing APOE3 (n = 25) or APOE4 (n = 17). d, CSF IL1β levels in individuals with CDR 0 bearing APOE3 (n = 43) or APOE4 (n = 18), and with CDR 0.5 bearing APOE3 (n = 17) or APOE4 (n = 13). (e) CSF TNFα levels in individuals with CDR 0 bearing APOE3 (n = 70) or APOE4 (n = 46), and with CDR 0.5 bearing APOE3 (n = 34) or APOE4 (n = 32). f, CSF soluble intercellular adhesion molecule 1 (sICAM1) levels in individuals with CDR 0 bearing APOE3 (n = 77) or APOE4 (n = 40), and with CDR 0.5 bearing APOE3 (n = 39) or APOE4 (n = 33). g, CSF NSE levels in individuals with CDR 0 bearing APOE3 (n = 47) or APOE4 (n = 32), and with CDR 0.5 bearing APOE3 (n = 29) or APOE4 (n = 29). Continuous lines, median; dotted lines, IQR. a and b had one outlier each, which were removed before statistical analysis (see Methods). Significance by ANCOVAs for main effects and post hoc comparisons controlling for age, sex, and education.
